By the introduction of novel endocrine agents, targeted agents and immunotherapy, a substantial progress has been made for both hormone-receptor-positive as well as human epidermal growth factor receptor 2 (HER2/neu) positive metastatic breast cancers [3]. The gene discussed is ERBB2; the disease is breast carcinoma.